Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 11
Submit an article Journal homepage
233
Views
6
CrossRef citations to date
0
Altmetric
Drug Profiles

Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy

Richard WeislerDepartment of Psychiatry, University of North Carolina at Chapel Hill, Raleigh, NC, USA;Department of Psychiatry & Behavioral Science, Duke University Medical Center, Durham, NC, USACorrespondence[email protected]
,
Roger S McIntyreDepartment of Psychiatry, University Health Network, Toronto Western Hospital, Toronto, ON, CanadaCorrespondence[email protected]
&
Michael BauerDepartment of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyCorrespondence[email protected]
Pages 1183-1200 | Published online: 09 Jan 2014

References

  • Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 3(11), e442 (2006).
  • Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: How did it change between 1990 and 2000? J. Clin. Psychiatry, 64(12), 1465–1475 (2003).
  • Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J. Ment. Health Policy Econ. 9(2), 87–98 (2006).
  • Bauer M, Bschor T, Pfennig A et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J. Biol. Psychiatry 8(2), 67–104 (2007).
  • Nemeroff CB. Prevalence and management of treatment-resistant depression. J. Clin. Psychiatry 68 (Suppl. 8) 17–25 (2007).
  • Rush AJ. Limitations in efficacy of antidepressant monotherapy. J. Clin. Psychiatry 68(Suppl. 10), 8–10 (2007).
  • Nierenberg AA, Husain MM, Trivedi MH et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol. Med. 40(1), 41–50 (2010).
  • Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiatry 157(9), 1501–1504 (2000).
  • Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev. Neurother. 9(7), 975–984 (2009).
  • Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J. Clin. Psychiatry 70(Suppl. 6), 16–25 (2009).
  • Howland RH, Shutt LS, Berman SR, Spotts CR, Denko T. The emerging use of technology for the treatment of depression and other neuropsychiatric disorders. Ann. Clin. Psychiatry 23(1), 48–62 (2011).
  • Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann. Intern. Med. 143(6), 415–426 (2005).
  • Gourion D. [Antidepressants and their onset of action: a major clinical, methodological and pronostical issue]. Encephale 34(1), 73–81 (2008).
  • Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am. J. Gastroenterol. 104(6), 1475–1482 (2009).
  • Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr. Med. Res. Opin. 19(2), 114–124 (2003).
  • Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J. Clin. Psychopharmacol. 29(3), 259–266 (2009).
  • Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum. Psychopharmacol. 20(8), 533–559 (2005).
  • Papakostas GI. Limitations of contemporary antidepressants: tolerability. J. Clin. Psychiatry 68(Suppl. 10), 11–17 (2007).
  • Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J. Clin. Psychopharmacol. 17(3), 208–221 (1997).
  • Fava M. Weight gain and antidepressants. J. Clin. Psychiatry 61(Suppl. 11), 37–41 (2000).
  • Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am. J. Psychiatry 166(5), 591–598 (2009).
  • Raeder MB, Bjelland I, Emil VS, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J. Clin. Psychiatry 67(12), 1974–1982 (2006).
  • Whang W, Kubzansky LD, Kawachi I et al. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses’ Health Study. J. Am. Coll. Cardiol. 53(11), 950–958 (2009).
  • van Noord C, Straus SM, Sturkenboom MC et al. Psychotropic drugs associated with corrected QT interval prolongation. J. Clin. Psychopharmacol. 29(1), 9–15 (2009).
  • Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin. Drug Saf. 2(3), 249–262 (2003).
  • Siegler EL, Tamres D, Berlin JA, Allen-Taylor L, Strom BL. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch. Intern. Med. 155(9), 953–957 (1995).
  • Spigset O, Hedenmalm K. Hyponatremia during treatment with clomipramine, perphenazine, or clozapine: study of therapeutic drug monitoring samples. J. Clin. Psychopharmacol. 16(5), 412–414 (1996).
  • Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry 68(2), 224–236 (2007).
  • Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(6), 843–853 (2007).
  • Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 14(4), 197–206 (2009).
  • Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28(2), 156–165 (2008).
  • Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 166(9), 980–991 (2009).
  • Kahn RS, Schulz SC, Palazov VD et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(6), 832–842 (2007).
  • Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin. Ther. 23(11), 1839–1854 (2001).
  • Addington DE, Mohamed S, Rosenheck RA et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J. Clin. Psychiatry 72(1), 75–80 (2011).
  • Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin. Ther. 33(11), 1643–1658 (2011).
  • Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr. Med. Res. Opin. 21(6), 923–934 (2005).
  • Calabrese JR, Keck PE Jr., Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162(7), 1351–1360 (2005).
  • McElroy SL, Weisler RH, Chang W et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J. Clin. Psychiatry 71(2), 163–174 (2010).
  • Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J. Affect. Disord. 121(1-2), 106–115 (2010).
  • Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26(6), 600–609 (2006).
  • Young AH, McElroy SL, Bauer M et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J. Clin. Psychiatry 71(2), 150–162 (2010).
  • Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect. Disord. 109(3), 251–263 (2008).
  • Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am. J. Psychiatry 166(4), 476–488 (2009).
  • Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J. Clin. Psychiatry. 72(11), 1452–1464 (2011).
  • Young AH, McElroy SL, Olausson B, Paulsson B. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J. Biol. Psychiatry (doi:10.3109/15622975.2012.665177) (2012) (Epub ahead of print).
  • Goldstein JM, Arvanitis LA. ICI 204,636 (SEROQUEL™): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev. 1(1), 50–73 (1995).
  • Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 33(10), 2303–2312 (2008).
  • Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur. Psychiatry 25(Suppl. 1), 1446, abstract PW01–27 (2010).
  • Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’? Clin. Neurosci. Res. 3(1–2), 108–117 (2003).
  • Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47(1), 27–38 (2002).
  • Goldstein JM, Nyberg S, Brecher M. Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. Eur. Psychiatry 23(Suppl. 2) (2008).
  • Stahl S. Psychopharmacology of antidepressants. Martin Dunitz Ltd, London, UK (2008).
  • Hudzik T, Zhou J, Brockel B et al. Further characterization of norquetiapine and quetiapine in rodent models of antidepressant and anxiolytic action. Eur. Psychiatry 18(Suppl. 4), S351–S352 (2008).
  • Bjorkholm C, Jardemark K, Marcus MM et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur. Neuropsychopharmacol. 23(7), 709–720 (2013).
  • Nyberg S, Takano A, Jucaite A et al. PET-measured occupancy of the NET by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects. Eur. Neuropsychopharmacol. 18(4), S270 (2008).
  • Hirschfeld RM, Montgomery SA, Aguglia E et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry 63(9), 826–837 (2002).
  • Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int. J. Neuropsychopharmacol. 3(4), 339–349 (2000).
  • Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin. Ther. 31(3), 492–502 (2009).
  • Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(2), 199–204 (2009).
  • Juckel G, Winter HR, Ståhle L, Miller F, Strid S. The pharmacokinetics of extended release quetiapine fumarate are not affected by a light meal. Schizophr. Res. 98(Suppl.), 163 (2008).
  • DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin. Pharmacokinet. 40(7), 509–522 (2001).
  • Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J. Clin. Psychiatry 63(Suppl. 13), 5–11 (2002).
  • Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187(4), 415–423 (2006).
  • Khullar A, Chokka PR, Fullerton D, McKenna SP, Blackman A. A double blind, randomized, placebo controlled study of quetiapine as augmentation therapy to SSRI/SNRI agents in the treatment of non-psychotic unipolar depression with residual symptoms. Proceedings of the American Psychiatric Association 159th Annual Meeting. Toronto, Canada, 20–25 May (2006).
  • Mattingly G, Ilivicky H, Canale J, Anderson R. Quetiapine combination for treatment-resistant depression. Proceedings of the American Psychiatric Association 159th Annual Meeting. Toronto, Canada, 20–25 May (2006).
  • McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors (SSRIs) or venlafaxine in patients with major depression, comorbid anxiety and residual depressive symptoms: a randomized, placebo controlled pilot study. Depress. Anxiety 24(7), 487–494 (2007).
  • El-Khalili N, Joyce M, Atkinson S et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 13(7), 917–932 (2010).
  • Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J. Clin. Psychiatry 70(4), 540–549 (2009).
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC (2000).
  • Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J. Affect. Disord. 127(1–3), 19–30 (2010).
  • AstraZeneca. Data on file. AstraZeneca plc, London, UK.
  • El-Khalili N, Bauer M, Datto C, Earley W, Astrom M, Eriksson HA. Pooled analysis of adjunctive extended release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder (MDD). Eur. Psychiatry 24(2), P01-249 (2009).
  • Chang CK, Hayes RD, Broadbent M et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 10, 77 (2010).
  • Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 64(2), 161–174 (2003).
  • Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J. Affect. Disord. 84(2-3), 149–157 (2005).
  • Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rössler W. Diagnostic issues in bipolar disorder. Eur. Neuropsychopharmacol. 13(Suppl. 2), S43–S50 (2003).
  • Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59(6), 530–537 (2002).
  • Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60(3), 261–269 (2003).
  • Hirschfeld RM, Vornik LA. Recognition and diagnosis of bipolar disorder. J. Clin. Psychiatry 65(Suppl. 15), 5–9 (2004).
  • Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. J. Affect. Disord. 84(2–3), 117–125 (2005).
  • Rosa AR, Andreazza AC, Kunz M et al. Predominant polarity in bipolar disorder: diagnostic implications. J. Affect. Disord. 107(1–3), 45–51 (2008).
  • Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J. Clin. Psychiatry 69(11), 1751–1757 (2008).
  • Zimmerman M, Ruggero CJ, Chelminski I, Young D. Is bipolar disorder overdiagnosed? J. Clin. Psychiatry 69(6), 935–940 (2008).
  • Mitchell PB. Bipolar disorder: the shift to overdiagnosis. Can. J. Psychiatry 57(11), 659–665 (2012).
  • Zimmerman M, Galione JN, Attiullah N et al. Underrecognition of clinically significant side effects in depressed outpatients. J. Clin. Psychiatry 71(4), 484–490 (2010).
  • Phelps J, Ghaemi SN. The mistaken claim of bipolar ‘overdiagnosis’: solving the false positives problem for DSM-5/ICD-11. Acta Psychiatr. Scand. 126(6), 395–401 (2012).
  • Wade A, Friis AH. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr. Med. Res. Opin. 22(11), 2101–2110 (2006).
  • Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J. Clin. Psychiatry 69(6), 946–958 (2008).
  • Lam RW, Kennedy SH, Grigoriadis S et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J. Affect. Disord. 117(Suppl. 1), S26–S43 (2009).
  • Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry 71(4), 451–462 (2010).
  • Thase ME, Trivedi MH, Nelson JC et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim. Care Companion. J. Clin. Psychiatry 10(6), 440–447 (2008).
  • Mahmoud RA, Pandina GJ, Turkoz I et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann. Intern. Med. 147(9), 593–602 (2007).
  • Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 10(3), e1001403 (2013).
  • Perlis RH, Ostacher M, Fava M, Nierenberg AA, Sachs GS, Rosenbaum JF. Assuring that double-blind is blind. Am. J. Psychiatry 167(3), 250–252 (2010).
  • Montgomery SA. Impact of methodology on the efficacy of extended release quetiapine fumarate in major depressive disorder. Eur. Neuropsychopharmacol. 20(Suppl. 3), S353 (2010).
  • Bauer M, Demyttenaere K, El-Khalili N et al. Efficacy of adjunct quetiapine XR in major depressive disorder: a pooled analysis of SSRI and SNRI patient subgroups. Eur Neuropsychopharmacol. 21(Suppl. 3), S441–S442 (2011).
  • Endicott J, Paulsson B, Gustafsson U, Schiöler H, Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J. Affect. Disord. 111(2–3), 306–319 (2008).
  • Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress. Anxiety 27(10), 964–976 (2010).
  • Montejo-Gonzalez AL, Llorca G, Izquierdo JA et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther. 23(3), 176–194 (1997).
  • Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann. Intern. Med. 144(4), 257–261 (2006).
  • Nelson JC, Thase ME, Trivedi MH et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim. Care Companion J. Clin. Psychiatry 11(6), 344–352 (2009).
  • Fava M, Wisniewski SR, Thase ME et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J. Clin. Psychopharmacol. 29(4), 362–367 (2009).
  • Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychiatry 69(8), 1228–1336 (2008).
  • Fawcett J, Scheftner WA, Fogg L et al. Time-related predictors of suicide in major affective disorder. Am. J. Psychiatry 147(9), 1189–1194 (1990).
  • Weisler R, Montgomery SA, Eriksson H, Szamosi J. Extended release quetiapine fumarate (quetiapine XR) in acute and maintenance studies in major depressive disorder (MDD): suicidality data. Int. J. Psychiatry Clin. Pract. 13(Suppl. 1), 45 (2009).
  • Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905–1917 (2006).
  • Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J. Clin. Psychiatry 72(11), 1503–1514 (2011).
  • Fava M, Shelton RC, Zajecka J et al. l-methylfolate augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder: results of two randomized, double-blind trials. Neuropsychopharmacology 35(Suppl. 1s), S100 (2010).
  • Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am. J. Psychiatry 167(8), 942–948 (2010).
  • Kemp DE, Ismail-Beigi F, Ganocy SJ et al. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J. Affect. Disord. 136(3), 1164–1173 (2012).
  • Salehi-Sadaghiani M, Javadi-Paydar M, Gharedaghi MH et al. NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacology (Berl) 223(3), 345–355 (2012).
  • Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37(9), 2093–2100 (2012).
  • Diazgranados N, Ibrahim L, Brutsche NE et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67(8), 793–802 (2010).
  • Zarate CA Jr, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63(8), 856–864 (2006).
  • Diazgranados N, Ibrahim LA, Brutsche NE et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 71(12), 1605–1611 (2010).
  • Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72(10), 1313–1333 (2012).
  • Holsboer F, Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. Eur. J. Pharmacol. 583(2–3), 350–357 (2008).
  • Nielsen DM. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? Life Sci. 78(9), 909–919 (2006).
  • Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165(5), 617–620 (2008).
  • Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin. Investig. Drugs 20(8), 1107–1130 (2011).
  • Rethorst CD, Trivedi MH. Evidence-based recommendations for the prescription of exercise for major depressive disorder. J. Psychiatr. Pract. 19(3), 204–212 (2013).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.